Bcl-XL levels were related to radioresistance in glioma [36] and Mcl-1 proteins regulate temozolomide efficacy in glioma independently of MGMT promoter methylation status.[37] Here, we found that MGMT promoter methylation status and tumor recurrence, which normally determine patient overall outcome[4], were not related to the applied treatments either. The gene discussed is BCL2L1; the disease is central nervous system cancer.